JC10 Rec'd PCT/PTO 2 1 JUL 2005

IN THE STATES PATENT AND TRAMMARK OFFICE

PC1 #3

In re Patent Application of

VERVAET et al.

Serial No.

10/537,301

Filed:

June 2, 2005

JUL 2 1 2005 CS

Atty. Ref.:

2551-170

Group:

Unasssigned

Examiner:

Unassigned

For:

PHARMACEUTICAL COMPOSITIONS OF CELL LYSATE

AND PROCESSES FOR THE PRODUCTION AND USE

THEREOF


Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

July 21, 2005

Šir:

INFORMATION DISCLOSURE STATEMENT

冈 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)** [within 3 months of filing or prior to 1st Office Action on the merits] N/C 2.(a) Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] N/C 2 .(b) Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] \$180.00 3. Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment] \$180.00



4. A list of documents on the attached PTO-1449 Form together with copies of USP 5,866,167, USP 6,046,178 and WO 97/41899 listed on PTO-1449 Form filed June 2, 2005, are enclosed herewith. Return of an initialed copy of the attached PTO-1449 Form along with PTO-1449 Form filed June 2, 2005, pursuant to MPEP Section 609, is requested.

This paper is submitted in accordance with:

\boxtimes	5.	37 (CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]				
	6.	37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and					
		a)	The required Statement made in item 8 below; or				
		b)	The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.				
	7.	37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement <u>and</u> Rule 17(p) fee), but before final fee payment]; and					
		a)	The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and				
		b)	The required Statement is stated in item 8 below.				
	8.	Statement under 37 CFR 1.97(e)					
		a)	The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or				
		b)	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37				



CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted, NIXON & VANDERHYE P.C.

/:

Reg. No. 36,663

901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

		OTHER	DOCUM	ENTS (in	cluding A	uthor, Title, Date	, Pertinent	pages, etc.)	
*Examir	ner					Date Considered			

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)